AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$MAIA

Guerrero Ramiro purchased $50K of MAIA

Guerrero Ramiro purchased 37,595 shares of MAIA Biotechnology, Inc. (MAIA) at $1.32 on 2026-09-10.

Original reporting
SEC EDGAR · Guerrero Ramiro
Published Sep 14, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 1:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MAIA
Neutral
medium confidence
Mentioned
$MAIA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAIANeutralLow
01

Why it matters

The transaction is a primary disclosure but small in scale, offering limited trading insight.

02

Market read

Minor insider buy; unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 4/10Novelty 5/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions. Director purchases are publicly reported.

Company-level read

Ticker impact

$MAIANeutralMedium confidence
Context

Director Guerrero Ramiro bought 37,595 shares of MAIA for $49.5K, increasing his stake to 773,296 shares.

Expected impact

Minor upward pressure, likely negligible on market price.

Evidence & confidence

Purchase size is modest relative to float; director buying is a positive signal but not material.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Limited to MAIA shareholders.

Counterpoint

What could challenge this read

Insider purchase could be routine portfolio rebalancing, not a strong buy signal.

Key entities

  • Company
    MAIA Biotechnology, Inc.

    Biotech firm listed on NASDAQ.

  • Insider
    Guerrero Ramiro

    Director of MAIA who purchased shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MAIA insider trading history →

Related articles

OCT 7
$MAIAMedAI 8/10

MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%

MAIA Biotechnology (MAIA) announced completing enrollment for Part C of its Phase 2 THIO-101 trial and 65% completion for its Phase 3 THIO-104 trial, both evaluating ateganosine in NSCLC. The company reported a 90.5% interim disease control rate for the combination therapy. MAIA aims to enroll 100 patients in THIO-104 by 2026, with an interim analysis planned for 2027. The FDA granted Fast Track designation to ateganosine in July 2025. MAIA shares are up 0.85% at $1.20.

rttnews.com2 min
OCT 7
$MAIAMedAI 9/10

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.

globenewswire.com2 min